Drug Profile

CGC 738

Alternative Names: CD70-targeted CAR-NKT Cells; CGC-738

Latest Information Update: 19 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CureGenetics
Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

11 Mar 2025 RenJi Hospital plans a phase I trial for Renal cell carcinoma (Late stage disease, Metastatic disease, Second-line therapy or greater) (Parenteral, Injection) in March 2025 (NCT06870279)
14 Nov 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Recurrent, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT06728189)
14 Nov 2024 Preclinical trials in Solid tumours in China (Parenteral) Prior to November 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com